Megakaryocyte cell sorting from diosgenin-differentiated human erythroleukemia cells by sedimentation field-flow fractionation.
Anticancer differentiation therapy could be one strategy to stop cancer cell proliferation. Human erythroleukemia (HEL) cell line, incubated with 10 microM diosgenin, underwent megakaryocytic differentiation. Thus, the association diosgenin/HEL could be used as a model of chemically induced cellular differentiation and anticancer treatment. The goal of this work was to determine the capacity of sedimentation field-flow fractionation (SdFFF) to sort megakaryocytic differentiated cells. SdFFF cell sorting was associated with cellular characterization methods to calibrate specific elution profiles. As demonstrated by cell size measurement methods, cellular morphology, ploidy, and phenotype, we obtained an enriched, sterile, viable, and functional fraction of megakaryocytic cells. Thus, SdFFF is proposed as a routine method to prepare differentiated cells that will be further used to better understand the megakaryocytic differentiation process.
Léger
D Y
DY
Laboratoire de Biochimie, EA 4021 "Biomolécules et Thérapies Anti-tumorales," Université de Limoges, Faculté de Pharmacie, 87025 Limoges Cedex, France.
Battu
S
S
Liagre
B
B
Beneytout
J L
JL
Cardot
P J P
PJ
D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D002469:Cell Separation / Q000379:methods*; D048429:Cell Size / Q000187:drug effects; D004144:Diosgenin / Q000494:pharmacology*; D031521:Fractionation, Field Flow / Q000379:methods*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology / Q000503:physiopathology; D008533:Megakaryocytes / Q000166:cytology* / Q000502:physiology; D040201:Platelet Membrane Glycoprotein IIb / Q000032:analysis
D040201:Platelet Membrane Glycoprotein IIb; D004144:Diosgenin